SCHEMBL17754841

SCHEMBL17754841

CC(C)(C)OC(=O)N1CCC(n2cc(-c3cnc4cnn(Cc5cnc6ccc(-c7cnn(C8CCN(C(=O)OC(C)(C)C)CC8)c7)nn56)c4c3)cn2)CC1

nearest known ligand 0.52

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MET P08581 6/20 0.52
FGFR1 P11362 2/20 0.45
FGFR2 P21802 2/20 0.45
FGFR4 P22455 2/20 0.45
FGFR3 P22607 2/20 0.45
KDR P35968 2/20 0.45
FLT3 P36888 2/20 0.45
LIPC P11150 1/20 0.39
RIPK2 O43353 1/20 0.39
RET P07949 1/20 0.39
TTK P33981 2/20 0.39
TNK2 Q07912 1/20 0.38
GPR119 Q8TDV5 2/20 0.37
DDB1 Q16531 1/20 0.37
CRBN Q96SW2 1/20 0.37
CCNC P24863 1/20 0.36
CDK8 P49336 1/20 0.36
PIK3CA P42336 1/20 0.36
MTOR P42345 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17754837 0.92 MET (0.51) METFGFR1FGFR2FGFR4FGFR3
SCHEMBL20215089 0.91 MET (0.50) METFGFR1FGFR2FGFR4FGFR3
SCHEMBL17754827 0.89 MET (0.54) METFGFR1FGFR2FGFR4FGFR3
SCHEMBL17754939 0.85 MET (0.51) METFGFR1FGFR2FGFR4FGFR3
SCHEMBL17754824 0.85 MET (0.56) METFGFR1FGFR2FGFR4FGFR3
SCHEMBL17754840 0.84 MET (0.51) METFGFR1FGFR2FGFR4FGFR3
SCHEMBL16367799 0.84 MET (0.52) METFGFR1FGFR2FGFR4FGFR3
SCHEMBL17754829 0.81 MET (0.54) METFGFR1FGFR2FGFR4FGFR3
SCHEMBL20215771 0.80 MET (0.47) METFGFR1FGFR2FGFR4FGFR3
SCHEMBL22045729 0.78 MET (0.55) METFGFR1FGFR2FGFR4FGFR3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9988381-B2 Five-member-heterocycle fused pyridine compounds, method of producing the same, and use thereof SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) 2018-06-05 US disclosed
US-20160137640-A1 FIVE-MEMBER-HETEROCYCLE FUSED PYRIDINE COMPOUNDS, METHOD OF PRODUCING THE SAME, AND USE THEREOF SHANGHAI HAIHE PHARMACEUTICAL CO. LTD. (CN) 2016-05-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160137640-A1 FIVE-MEMBER-HETEROCYCLE FUSED PYRIDINE COMPOUNDS, METHOD OF PRODUCING THE SAME, AND USE THEREOF ABL1, JAK2, LCK MET 213/4885FGFR1 68/4885FGFR2 183/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.